Department of Gynecology, The First Affiliated Hospital With Nanjing Medical University (Jiangsu Province Hospital), Nanjing, China.
Cancer Control. 2023 Jan-Dec;30:10732748231195716. doi: 10.1177/10732748231195716.
This retrospective study aims to investigate the feasibility of using carbon nanoparticles to detect sentinel lymph nodes (SLNs) in cervical cancer.
This study involved 174 patients with cervical cancer. Cervix tissues adjacent to the cancer were injected with 1 mL of carbon nanoparticles (CNPs) at the 3 and 9 o'clock positions according to the instructions. The pelvic lymph nodes were then dissected, and the black-stained sentinel lymph nodes were sectioned for pathological examination.
Of 174 cases, 88.5% of patients (154/174) had at least 1 sentinel lymph node, and 131 patients (75.29%) had bilateral pelvic sentinel lymph nodes. The left pelvic lymph node was the most common sentinel lymph node (34.16%). At least 1 sentinel lymph node was observed in 285 out of 348 hemipelvises, with a detection rate of a side-specific sentinel lymph node of 81.89%. In total, 47 hemipelvises had metastasis of the lymph node, and 33 involved the sentinel lymph node, with a sensitivity of 70.21% and a false-negative rate of 29.79%. There were 238 hemipelvises with no metastasis of the lymph node, as well as negative sentinel lymph nodes, with a specificity of 100% and a negative predictive value of 94.44%. The univariate analysis demonstrated that risk factors included tumor size (OR .598, 95% CI: .369-.970) and deep stromal invasion (OR .381, 95% CI: .187-.779). The deep stromal invasion was the only variable for the false-negative detection of a sentinel lymph node.
Sentinel lymph node mapping with carbon nanoparticles might be applied to predict the metastasis of pelvic lymph nodes in cervical cancer. However, tumor size and deep stromal invasion might negative influence the detection rate of SLN.
本回顾性研究旨在探讨使用碳纳米粒子检测宫颈癌前哨淋巴结(SLN)的可行性。
本研究纳入了 174 例宫颈癌患者。根据说明书,在癌症周围的宫颈组织的 3 点和 9 点位置注射 1ml 碳纳米粒子(CNPs)。然后解剖盆腔淋巴结,对黑色染色的前哨淋巴结进行切片进行病理检查。
在 174 例病例中,88.5%(154/174)的患者至少有 1 个前哨淋巴结,131 例(75.29%)的患者有双侧盆腔前哨淋巴结。左盆腔淋巴结是最常见的前哨淋巴结(34.16%)。在 348 个半骨盆中,至少有 1 个前哨淋巴结的有 285 个,一侧前哨淋巴结的检出率为 81.89%。总共 47 个半骨盆的淋巴结发生了转移,其中 33 个涉及前哨淋巴结,敏感性为 70.21%,假阴性率为 29.79%。238 个半骨盆的淋巴结没有转移,前哨淋巴结也没有转移,特异性为 100%,阴性预测值为 94.44%。单因素分析表明,肿瘤大小(OR.598,95%CI:.369-.970)和深肌层浸润(OR.381,95%CI:.187-.779)是危险因素。深肌层浸润是前哨淋巴结假阴性检测的唯一变量。
碳纳米粒子示踪法可能应用于预测宫颈癌盆腔淋巴结的转移。然而,肿瘤大小和深肌层浸润可能会对 SLN 的检出率产生负面影响。